Featured Research

from universities, journals, and other organizations

Estrogen May Play Role In Prevention Of Cataracts

Date:
October 11, 1999
Source:
Indiana University
Summary:
Indiana University School of Medicine researchers have shown that optic lens cells may be added to the growing list of parts of the body found to be sensitive to the hormone estrogen.

INDIANAPOLIS -- Indiana University School of Medicine researchers have shown that optic lens cells may be added to the growing list of parts of the body found to be sensitive to the hormone estrogen.

Lens cells have receptors for estrogen, adding further evidence to epidemiological research showing that estrogen may play a role in preventing cataracts in aging women. The new work was published in the August 3 issue of Proceedings of the National Academy of Science. Robert M. Bigsby, Ph.D., associate professor of obstetrics and gynecology is the lead author.

In the study, researchers removed the ovaries of rats before treating them with methylnitrosourea, a carcinogenic compound that causes breast cancer in laboratory animals.

The rats were divided into groups that received no estrogen, estradiol (the predominant natural estrogen in pre-menopausal women) or estrone (the predominant natural estrogen in post-menopausal women).

Within six to eight months, 74 percent of the rats receiving no estrogen developed a type of cataract similar to age-related cataracts seen in humans. Only 12 percent of the rats treated with estradiol and 25 percent of those treated with estrone developed cataracts.

"This experimental model gives credence to the epidemiological studies that estrogens are protective against cataracts," said Dr. Bigsby.

Seventy-five percent of people over the age of 75 exhibit some degree of cataracts. It is estimated that more than 50 percent of cases of blindness are caused by cataracts. Age-related cataracts affect more women than men, and one study of women with early onset of menopause showed a 2.9-fold risk of developing cataracts.

"We now have an animal model system that will allow us to determine if the different types of estrogens used in post-menopausal hormone replacement therapy will also prove protective against cataracts," Dr. Bigsby said.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Estrogen May Play Role In Prevention Of Cataracts." ScienceDaily. ScienceDaily, 11 October 1999. <www.sciencedaily.com/releases/1999/10/991011081856.htm>.
Indiana University. (1999, October 11). Estrogen May Play Role In Prevention Of Cataracts. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/10/991011081856.htm
Indiana University. "Estrogen May Play Role In Prevention Of Cataracts." ScienceDaily. www.sciencedaily.com/releases/1999/10/991011081856.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins